Stock Expert AI

EDEN (EDEN) ETF Analysis

EDEN is an ETF providing exposure to a concentrated portfolio of 10 primarily Danish companies. Its top holdings include Novo Nordisk, DSV, and Danske Bank.

With a dividend yield of 2.95% and a beta of 0.87, EDEN offers a potentially attractive income stream with moderate volatility relative to the broader market. Investors should note the fund's concentrated nature, which can amplify both gains and losses compared to more diversified ETFs.

EDEN (EDEN) ETF — Price, Holdings & Analysis

EDEN is an ETF providing exposure to a concentrated portfolio of 10 primarily Danish companies. Its top holdings include Novo Nordisk, DSV, and Danske Bank. With a dividend yield of 2.95% and a beta of 0.87, EDEN offers a potentially attractive income stream with moderate volatility relative to the broader market. Investors should note the fund's concentrated nature, which can amplify both gains and losses compared to more diversified ETFs.

ETF-Übersicht

EDEN offers targeted exposure to a select group of European companies, primarily based in Denmark. Unlike broad-based European ETFs, EDEN employs a highly concentrated strategy, holding only 10 companies. This approach allows investors to gain focused exposure to specific businesses, potentially leading to outperformance if these companies thrive. The fund's top holdings include Novo Nordisk AS Class B (18.04%), DSV AS (11.87%), and Danske Bank AS (7.81%), reflecting a bias towards healthcare, transportation, and financial sectors. Investors seeking diversified exposure to the European market may find EDEN's concentrated approach less suitable, while those seeking targeted exposure to specific companies or sectors within Europe may find it appealing. EDEN's concentrated portfolio means that the performance of a few key holdings will significantly impact the overall return of the fund.

Risikokennzahlen

EDEN's concentrated portfolio of only 10 holdings introduces significant concentration risk. A downturn in any of its top holdings, such as Novo Nordisk or DSV, could disproportionately impact the fund's performance. The fund's beta of 0.87 indicates that it is less volatile than the overall market, but this does not mitigate the concentration risk. Investors should also consider the potential impact of currency fluctuations, as the fund invests in European companies. While EDEN's expense ratio is not explicitly provided, it's important to factor in expense drag, which can erode returns over time. The fund's sector allocation also presents a risk, as a significant portion of its assets are concentrated in healthcare, transportation, and financials. Past performance does not guarantee future results.

Was hält EDEN?

PositionGewichtung
Novo Nordisk AS Class B (NOVO-B.CO)18.04%
DSV AS (DSV.CO)11.87%
Danske Bank AS (DANSKE.CO)7.81%
Vestas Wind Systems AS (VWS.CO)4.85%
Novonesis (Novozymes) B Class B (NSIS-B.CO)4.57%
Genmab AS (GMAB.CO)4.33%
Carlsberg AS Class B (CARL-B.CO)3.84%
Orsted AS (ORSTED.CO)3.36%
A P Moller Maersk AS Class B (MAERSK-B.CO)2.68%
Coloplast AS Class B (COLO-B.CO)2.39%

Dividendenrendite

2.95%

Risikokennzahlen

  • Beta: 0.87

Fragen & Antworten

What is EDEN and what does it track?

EDEN is an exchange-traded fund that provides investors with exposure to a concentrated portfolio of primarily Danish companies. Unlike broad-based ETFs that track a wide range of stocks, EDEN focuses on a select group of 10 companies.

What is the expense ratio for EDEN?

The expense ratio for EDEN is not explicitly provided in the available data. However, it is a crucial factor to consider when evaluating the fund's overall cost.

Expense ratios can vary significantly among ETFs, and a higher expense ratio can erode returns over time. When researching EDEN, investors should seek out the fund's official documentation to determine its expense ratio and compare it to similar ETFs in the same category.

What are the top holdings in EDEN?

EDEN's top holdings are heavily weighted towards a few key companies. As of 2026-03-15, the top three holdings are Novo Nordisk AS Class B (18.04%), DSV AS (11.87%), and Danske Bank AS (7.81%).

Other significant holdings include Vestas Wind Systems AS (4.85%) and Novonesis (Novozymes) B Class B (4.57%). These top holdings represent a significant portion of the fund's total assets, highlighting the fund's concentrated nature.

Is EDEN a good long-term investment?

Whether EDEN is a suitable long-term investment depends on an individual investor's risk tolerance and investment objectives. The fund's concentrated portfolio of 10 holdings introduces significant concentration risk, which could lead to greater volatility compared to more diversified ETFs.

On the other hand, the fund's dividend yield of 2.95% may be attractive to income-seeking investors.

How does EDEN compare to similar ETFs?

EDEN distinguishes itself from similar ETFs through its highly concentrated portfolio of just 10 holdings, primarily in Denmark. Many European ETFs offer broader diversification across numerous companies and countries.

While the expense ratio for EDEN is not provided, this is a key factor to compare against other ETFs.

Does EDEN pay dividends?

Yes, EDEN does pay dividends. The fund currently has a dividend yield of 2.95%. This means that for every $100 invested in EDEN, investors can expect to receive $2.95 in dividend payments annually, before any potential tax implications.

The dividend yield can fluctuate based on the fund's performance and the dividend policies of its underlying holdings. Investors seeking income may find EDEN's dividend yield attractive.